Charles River Laboratories Intl. Inc vs Monster Beverage Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $285.66 (market cap $13.46B), while Monster Beverage Corp trades at $45.5 (market cap $89.20B). The key difference: Monster Beverage Corp is far larger — about 6.6× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.
| CRL | MNST | |
|---|---|---|
Market Cap | $13.46B | $89.20B |
Sector | Health | Consumer Staples |
52-Week High | $282.00 | $49.97 |
52-Week Low | $145.57 | $30.86 |
Enterprise Value | $16.30B | $87.49B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Monster Beverage (MNST) trades at $45.53, down 0.35% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, maintaining robust profit margins above 23%. Recent Q2 2026 results exceeded expectations with $0.60 EPS versus $0.59 expected, driven by international growth. The stock completed a 2-for-1 split on August 11, 2026.
MNST presents a mixed outlook with strong earnings momentum and international expansion offset by premium valuation concerns. The stock trades at 42.16x P/E, above sector averages, while analyst consensus targets $51.14 suggest 12% upside. Key risks include competitive pressures in energy drinks and valuation sensitivity to growth sustainability.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →